News articles about ZIOPHARM Oncology (NASDAQ:ZIOP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.411264737673 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Oscillating Stocks-:- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), BP plc (NYSE:BP), Ophthotech Corporation (NASDAQ … – Market Breaking Point (press release) (journalfinance.net)
- Keryx Biopharmaceuticals : Today’s Research Reports on Trending Tickers: Keryx Biopharmaceuticals and ZIOPHARM Oncology (4-traders.com)
- ZIOP: Insiders Vs. Shorts (thestreet.com)
- ZIOPHARM to Present at the Stifel 2017 Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
A number of research analysts have commented on the stock. BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Friday, November 10th. Finally, HC Wainwright restated a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $12.58.
Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at $4.21 on Wednesday. ZIOPHARM Oncology has a fifty-two week low of $4.03 and a fifty-two week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.11) EPS. equities research analysts anticipate that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of ZIOPHARM Oncology stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.40% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect ZIOPHARM Oncology (ZIOP) Stock Price” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://weekherald.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-ziopharm-oncology-ziop-share-price.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.